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Abstract The purpose of this study was to evaluate the
distribution of the polymorphisms of the SCN1A gene in a
seriesofchildrenandadolescentswithprimaryheadacheand
idiopathic or cryptogenic epilepsy compared to controls.
Five non-synonymous exonic polymorphisms (1748A[T,
2656T[C, 3199A[G, 5771G[A, 5864T[C)
of the SCN1A gene were selected and their genotyping was
performed, by high resolution melting (HRM), in 49 cases
and 100 controls. We found that among the ﬁve poly-
morphisms, only 3199A[G was a true polymorphism.
We did not ﬁnd a statistically signiﬁcant difference between
distribution of 3199A[G genotypes between cases and
controls. We excluded the role of the SCN1A gene in the
pathogenesis of comorbidity between headache (especially
migraine) and epilepsy. The SCN1A gene is a major gene in
differentepilepsiesandepilepsysyndromes;theHRMcould
be the new methodology, more rapid and efﬁcacious,
for molecular analysis of the SCN1A gene.
Keywords Migraine  Epilepsy  Comorbidity 
SCN1A gene  Children
Introduction
Migraine and epilepsy are both common neurological dis-
orders and can occur as comorbid conditions [1–7]. From a
genetic point of view, migraine is a polygenic multifacto-
rial disorder [8], while many epilepsy syndromes are
monogenic and have been pathogenetically linked to
channelopathies [9]. Similarly familial hemiplegic
migraine (FHM), the only known autosomal subtype of
migraine, is due to mutations in genes encoding ion
channels, and it is often associated to epileptic seizures
[10]. Previous studies have excluded the role of the two
FHM genes (CACN1A, ATP1A2) in the common forms of
migraine [8, 11–13].
Considering the multifactorial etiology of migraine,
genetic studies on phenotypically homogenous populations
are required [8]. The comorbidity between two conditions
that share common pathogenetic mechanisms, such as
migraine and epilepsy, could address the issue.
The SCN1A gene encodes the a-subunit of the neuronal
voltage-gated sodium channel Nav1.1 (MIM# 182389).
Mutations in SCN1A are associated with a spectrum of
epilepsy syndromes [14]; a few mutations result in FHM
[15]. So far, SCN1A gene has never been investigated in
subjects with common forms of migraine.
The purpose of this study was to evaluate the role of the
SCN1A gene in the pathogenesis of comorbidity between
primary headache and idiopathic or cryptogenic epilepsy in
a large series of children and adolescents.
Materials and methods
This was a case–control study comparing the genotype
distribution and allele frequency of single nucleotide
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and healthy controls.
Fifty-six subjects out of 1,795 headache sufferers under
the age of 18 consecutively diagnosed at the juvenile
Headache Center of the Department of Pediatrics of Padua
Hospital between 1995 and 2008 were selected according
to the following criteria: (1) primary headache and (2)
idiopathic or cryptogenic epilepsy or unprovoked seizures.
Patients with secondary headache or symptomatic epilepsy
were excluded from the study. The methodology of
patients’ recruitment and phenotype selection has been
previously reported [7]. The study protocol and consent/
assent forms were approved by our Institutional Review
Board.
Forty-nine patients and 100 healthy controls participated
in the genetic study. All the healthy controls were inter-
viewed by a board certiﬁed child neurologist regarding, in
particular, the personal history of headache; those affected
by migraine or probable migraine, according to the criteria
of the International Classiﬁcation of Headache Disorders
(ICHD-II) [16] were excluded.
The molecular analysis was conducted at the Genetic
Laboratory of the Department of Pediatrics (University of
Padua). Parental informed consent for genetic testing was
obtained for each subject included in the study. Genomic
DNA was extracted from peripheral blood using the High
Pure PCR Template Preparation Kit (Roche Diagnostics
GmbH, Mannheim, Germany).
The ﬁve SNPs examined are described in Table 1.
Primers were designed using the Primer 3 software (http://
frodo.wi.mit.edu/primer3). Primer sequences and ampliﬁ-
cation conditions for SCN1A gene are available upon
request. Genotypes were determined by high resolution
melt (HRM) analysis [17–19].
The polymerase chain reaction (PCR) cycling and HRM
analysis were carried out sequentially on a Rotor Gene
6000 (Corbett Research, Mortlake, Australia) using Takara
Ex Taq R-PCR custom (Takara Bio Europe SAS,
Saint-Germain-en-Laye France). The HRM analysis was
performed with the temperature ramping (70 to 95C, rising
by 0.1C) and ﬂuorescence acquisition setting recommended
by the manufacturer. The melting curves were normalized
throughcalculationofthe‘‘lineofbestﬁt’’oftwonormalization
regions before and after the major ﬂuorescence drop,
corresponding to the melting of the PCR product using the
software provided with the Rotor Gene 6000 (Corbett
Research). Melting proﬁles and HRM running conditions were
determined experimentally in 10 reference controls that were
sequenced.
We obtained three different melting proﬁles only for the
3199A[G polymorphism. We sequenced two samples for
each melting proﬁle of each polymorphism, conﬁrming that
different proﬁles corresponded to different sequences.
Sequence analysis revealed that heterozygotes and homo-
zygotes have characteristic melting proﬁles that give rise to
differently shaped melting curves. Therefore, in the fol-
lowing HRM analyses we used the curves of homozygotes
and heterozygotes that were conﬁrmed by sequencing as
the reference for the genotype analysis of the unknown
samples.
Direct sequencing of PCR products with abnormal
HRM proﬁles was performed with the use of the BigDye

Terminator v1.1 Cycle Sequencing Kit (Applied Biosys-
tems) on ABI 310 automated DNA sequencer (PE
Applied Biosystems, Foster City, CA, USA). The HRM
proﬁles of cases with comorbidity were compared to
HRM proﬁles of healthy reference controls that were
sequenced.
The allele frequencies and genotypes in patients and
controls were calculated. Genotype distributions in patients
and controls were tested for Hardy–Weinberg equilibrium,
and differences in genotype frequencies between patients
and controls were tested using a Chi-square test for inde-
pendence, with a level of signiﬁcance set at 0.05.
Results
Among 1,795 headache sufferers under the age of 18
consecutively diagnosed at the juvenile Headache Center
of the Department of Pediatrics of Padua Hospital between
1995 and 2008, ﬁfty-six subjects having comorbidity
Table 1 Description of the polymorphisms of the SCN1A gene in this study
Base pair change Aminoacid Position Frequency of heterozygous
reported in literature
Clinical association Reference
c.1748A[T p.D583 V Exon 11 ND NK NCBI
c.2656T[C p.S886P Exon 15 ND NK NCBI
c.3199A[G p.T1067A Exon 16 0.33 The SNP is more frequent in patients
with epilepsy than in controls (33)
[24, 25, 27–33]
c.5771G[A p.R1924H Exon 26 ND NK NCBI
c.5864T[C p.I1955T Exon 26 0.025 NK [41]
ND not determined, NK not known
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123between primary headache and idiopathic or cryptogenic
epilepsy or unprovoked seizures were selected. The clinical
characteristics and the statistical analysis of these two
population study have been previously reported [7].
The present study focuses on the results of the SCN1A
gene molecular analysis, which was undertaken in 49 cases
and 100 healthy controls. Among the 49 cases, 45 subjects
(92%) had migraine (M) (38 migraine without aura, 7
migraine with aura) and 4 patients suffered from episodic
tension type (ETTH) headache. Considering the type of
epilepsy, there were 30 subjects with focal cryptogenic
epilepsy (27 M, 3 ETTH), 11 with focal idiopathic epilepsy
(10 M, 1 ETTH), and 8 (8 M, 0 ETTH) with idiopathic
generalized epilepsy.
The HRM proﬁles consist of three different graphs (melt
temperature, normalized graph and the difference graph)
that are visualized all together during the analysis of
results. As an example, we report the three graphs con-
cerning the HRM analysis of exon 16 (Fig. 1) and of exon
11 (Fig. 2).
Comparing the HRM proﬁles of the cases and healthy
control samples with those of the sequenced reference
controls, we could identify the genotypes of the samples
examined.
The polymorphism 3199A[G, having a signiﬁcant
heterozygosity (0.33), exhibited three HRM proﬁles con-
sistent with the three genotypes (AA, GA, GG), as con-
ﬁrmed by direct sequencing. The other four SNPs having a
low or not known heterozygosity disclosed a unique HRM
proﬁle, consistent with the wild type genotype.
During HRM analysis of exon 11, we found in one
patient a different proﬁle. The PCR product was analyzed
by direct sequencing that disclosed a missense variation
sequence 1811G[A that causes at protein level a
replacement of arginine with histidine (R604H). The
patient is a 15-year-old boy with a history of childhood
absence epilepsy (since 3–6) suffering from episodic ten-
sion headache, since the age of 11. He never experienced
febrile seizures or periodic syndromes. The analysis was
carried out in both the parents; the mother was negative
while the father, who was asymptomatic, carried the mis-
sense variation sequence 1811G[A.
During the analysis of healthy controls, we found in one
case a missense variation sequence 5782C[G that causes
at protein level a replacement of arginine with glycine
(R1928G).
The allele and genotype frequencies, respectively,
absolute and percentage, of the ﬁve SNPs observed in 49
patients and 100 healthy nonmigrainous controls, tested by
HRM, are presented in Table 2.
The analysis of the frequency distribution showed that,
only for the polymorphism 3199A[G, the two alleles (A:
wild type; G: mutated) are represented both in cases and
controls; while for the other four SNPs the allele frequency
of the wild type was 100% both in cases and controls, as
assessed on a total of 298 alleles, therefore these SNPs are
not true polymorphisms in the tested population. In the
case of polymorphism 3199A[G, the genotype distribu-
tions for the two alleles (A and G) were in equilibrium
under the Hardy–Weinberg law both in cases (p = 0.64)
and controls (p = 0.44) (with Chi-square test the balance is
present if p[0.05). For this polymorphism, the compari-
son of the distribution of allele (A, G) and genotype (A/A,
A/G, G/G) frequencies in cases and controls by Chi-square
test was not statistically signiﬁcant (respectively, p = 0.49,
p = 0.58).
Fig. 1 Rotor Gene 6000 HRM
normalized graph of the region
ampliﬁed for exon 16. SCN1A
3199A[G polymorphism;
green, homozygous for the A
allele (AA); red, homozygous
for the G allele (GG); blue,
heterozygous (AG)
J Headache Pain (2011) 12:435–441 437
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Previous studies have shown that cases affected by FHM,
carrying mutations of genes encoding ion channels
(CACNA1A, ATP1A2, SCN1A), may have seizures [20–
22].
Molecular analysis of the CACNA1A and ATP1A2 genes
in patients with migraine without aura and with aura, has
Fig. 2 Rotor Gene 6000 HRM
normalized graph of the region
ampliﬁed for exon 11. SCN1A
1748A[T polymorphism; red
(sequenced reference controls),
homozygous for the A allele
(AA); green (samples
examined), homozygous for the
A allele (AA)
Table 2 Allele and genotype frequencies, respectively absolute and percentage (in brackets), of the ﬁve SNPs of the SCN1A gene observed in 49
cases and 100 controls, tested by HRM
SNPs of the SCN1A gene
1748A[T 2656T[C 3199A[G 5771G[A 5864T[C
Cases (N = 49)
Allele frequencies A
98 (100%)
T
98 (100%)
A
65 (66.3%)
G
98 (100%)
T
98 (100%)
T
0 (0%)
C
0 (0%)
G
33 (33.7%)
A
0 (0%)
C
0 (0%)
Genotype frequencies A/A
49 (100%)
T/T
49 (100%)
A/A
22 (44%)
G/G
49 (100%)
T/T
49 (100%)
A/T
0 (0%)
T/C
0 (0%)
A/G
21 (44.7%)
G/A
0 (0%)
T/C
0 (0%)
T/T C/C G/G A/A C/C
0 (0%) 0 (0%) 6 (11.3%) 0 (0%) 0 (0%)
Controls (N = 100)
Allele frequencies A
200 (100%)
T
200 (100%)
A
123 (61.5%)
G
200 (100%)
T
200 (100%)
T
0 (0%)
C
0 (0%)
G
77 (38.5%)
A
0 (0%)
C
0 (0%)
Genotype frequencies A/A
100 (100%)
T/T
100 (100%)
A/A
42 (37.8%)
G/G
100 (100%)
T/T
100 (100%)
A/T
0 (0%)
T/C
0 (0%)
A/G
39 (47.4%)
G/A
0 (0%)
T/C
0 (0%)
T/T
0 (0%)
C/C
0 (0%)
G/G
19 (14.8%)
A/A
0 (0%)
C/C
0 (0%)
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123shown that these two genes are not involved in common
forms of migraine [8, 11–13], although similar studies have
not examined the SCN1A gene.
The comorbidity between migraine and epilepsy may
allow to select a clinically more homogeneous subgroup of
patients in order to carry out genetic studies more targeted
than those conducted in patients with common forms of
migraine.ThisisconﬁrmedbythestudyofDeprezetal.[23],
carriedouton20familieswithmigraineandepilepsy,which
showed mutations in the ATP1A2 gene in 10% of cases,
suggesting to perform molecular analysis of this gene in
cases where there is comorbidity between migraine and
epilepsyandpositivefamilyhistoryformigraineorepilepsy.
In our study, molecular analysis of ﬁve polymorphisms
in coding exons of the SCN1A gene was performed on a
large series consisting of 49 subjects with comorbidity
between primary headache and idiopathic or cryptogenic
epilepsy and 100 healthy nonmigrainous controls.
Among the ﬁve SNPs analyzed, only 3199A[G was
conﬁrmed to be a polymorphism while the other four SNPs
were not true polymorphisms, because they were not found
in the 298 alleles (cases and controls) examined and they
are not to be further investigated.
We did not ﬁnd a statistical signiﬁcant difference of
3199 A [ G genotypes’ distribution between cases and
controls; therefore our results conﬁrm that the polymor-
phism 3199A[G is not associated to pathological phe-
notypes in headache sufferers and in migraineurs, similar to
that found in other studies conducted on patients with
epilepsy.
From a statistical point of view, the group sample sizes
achieve a power lower than 20% to detect, as statistically
signiﬁcant, the observed differences between the two
groups for both allele and genotype analyses for the
polymorphism 3199A[G. Actually, those differences
could be considered negligible from a genetic point of view
when bearing in mind the epidemiological and clinical
characteristics of the disease. Furthermore, speciﬁcally in
reference to genotypes, the observed prevalence would
suggest that the A/A genotype is less prevalent among wild
type subjects, and this would be inconsistent with expected.
For these reasons, in our opinion, the results suggest that
the observed differences are due to chance.
To our knowledge, this is the ﬁrst study that has assessed
the genotype of polymorphisms in the SCN1A gene in cases
with comorbidity between headache and epilepsy.
The SCN1A gene has so far been well studied in large
series of patients with severe myoclonic epilepsy [24–26]
or in families with idiopathic generalized epilepsies and
febrile seizures plus (GEFS?)[ 27, 28] and also in some
families with febrile seizures [29].
These studies also contain data on the frequency
ofpolymorphism3199A[GofSCN1Agene,anddocumented
genotypic and allelic frequencies comparable between patients
and controls. The polymorphism 3199A[G was analyzed
speciﬁcally in patients with febrile convulsions [30]
or with migrainous vertigo [31] excluding a positive
correlation.
In two recent studies, the analysis of polymorphism
3199A[G of the SCN1A gene was conducted in Asiatic
patients affected by epilepsy [32, 33]; in both studies
genotype distributions in drug-responsive and drug-resis-
tant patients did not differ signiﬁcantly.
Only in the study of Lakhan et al. [33] a statistically
signiﬁcant correlation between the AG genotype of poly-
morphism 3199G[A and the presence of epilepsy in
cases compared to controls has been found; however, this
ﬁnding deserves further study because the statistical sig-
niﬁcance was observed only in heterozygous subjects, and
thus it is more difﬁcult to explain in terms of biological
plausibility. Overall, the results of the studies conducted so
far argue that the polymorphism 3199A[G of the SCN1A
gene is not associated with pathological phenotypes; our
results conﬁrm that this also applies to headache and
migraine sufferers.
We found a missense mutation 1811G[A (R604H) in
exon 11 in a patient with episodic tension headache and
childhood epilepsy with absences; in the literature this
mutation is already known [34–36]. Escayg et al. [34]
identiﬁed the same mutation in two patients with juvenile
myoclonic epilepsy and emphasized that this mutation
interrupts a consensus site for protein kinase A, which is
conserved in the four major sodium channel of the central
nervous system. However, this mutation did not cosegre-
gate with the epileptic phenotype in two families with
juvenile myoclonic epilepsy [34] and had a minor effect on
ionic currents in the study by Smith et al. [37]. The pos-
sibility that this mutation is not pathogenic has been sup-
ported by two subsequent works [35, 36]. In our case, the
pathogenetic signiﬁcance of this mutation was excluded by
carrying out the genetic analysis of the patient’s parents; in
fact the father was asymptomatic and carried the same
sequence variation.
We also conﬁrm that the missense variant 5782C[G
(R1928G), found in a single healthy nonmigrainous control
among the 100 examined, is a rare missense polymor-
phism, as previously reported [27, 36].
Our study seems to exclude a role of the SCN1A gene
in the pathogenesis of migraine and in particular in cases
with comorbidity between migraine and epilepsy. The
major limitation of the present study is that the genetic
analysis has been focused on a part of the gene, since a
complete genetic analysis seemed too expensive, given
the large number of exons (equal to 26) of the SCN1A
gene and based on the negative results in previous studies
[27, 38].
J Headache Pain (2011) 12:435–441 439
123Our data support the hypothesis [39], that the SCN1A
gene is not implicated in the pathogenesis of common
forms of migraine, even when the phenotype is restricted
by the presence of comorbidity with epilepsy.
The SCN1A gene has a causative role in some epilepsy
syndromes (severe myoclonic epilepsy and GEFS?) and
has recently been associated with new and different clinical
phenotypes, such as focal and generalized cryptogenic
epilepsy [35] and atypical Panayiotopoulos syndrome [40].
Another important aspect of this study was the use of an
innovative method, the HRM, for the molecular analysis
of the SCN1A gene. The HRM offers signiﬁcant advantages
over traditional methods (SSCP, DGGE, DHPLC, etc.), as
it does not require manipulation of genetic material after
ampliﬁcation, it is inexpensive, it has excellent sensitivity
and speciﬁcity and allows the concomitant analysis of a
large number of samples, increasing the reproducibility
of analysis and signiﬁcantly reducing the work time.
The sensitivity and speciﬁcity of variation detection of
HRM are estimated, respectively, to be 100 and 95% [19].
These characteristics are of particular relevance,
especially in the genetic analysis of multifactorial diseases,
such as headache and epilepsy, which requires a large
number of subjects and very often involves the analysis of
several polymorphisms in the same patients. The HRM
could then form the new method of molecular analy-
sis of the SCN1A gene, which is currently usually per-
formed with screening techniques (DHPLC) and direct
sequencing.
Conclusions
To the best of our knowledge, this is the ﬁrst study that
evaluated the association between polymorphisms of the
SCN1A gene and comorbidity between primary headache
(especially migraine) and epilepsy.
Our results conﬁrm that the polymorphism 3199A[G
is not associated with pathological phenotypes in patients
with headaches and migraine, while the other four poly-
morphisms examined were homozygous in the tested
populations and should not be further investigated.
We exclude the role of the SCN1A gene in the patho-
genesis of comorbidity between headache (especially
migraine) and epilepsy.
The SCN1A gene is a major gene in different epilepsies
and epilepsy syndromes, and in this ﬁeld it has to be further
investigated. The HRM could be a new methodology, more
rapid and efﬁcacious, for molecular analysis of the SCN1A
gene.
The development of protocols for more efﬁcient
and reliable molecular diagnostics would allow a wider
appreciation of the role of the SCN1A gene and of other
genes encoding for ion channels in different epilepsies and
epilepsy syndromes.
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